TTRX
Turn Therapeutics Inc.Company Information
- Company Name
- Turn Therapeutics Inc.
- CIK
- CIK0002023016
- Category
- <br>Emerging growth company
- Ticker: Exchange
- TTRX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- TTRX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-12-12
- Last sale
- —
- Shares purchased (TTM)
- 75,938
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,156,539
- Shares outstanding
- 29,788,040
- Ownership
- 3.88%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- -7.02%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||
| Cash Equivalents At Carrying Value | 10 | 11 | 5 | 3 | ||||||
| Cash And Cash Equivalents At Carrying Value | 10 | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 10 | 11 | 5 | 3 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | 1 | 1 | 1 | 1 | ||||||
| Deferred Costs | 6 | 6 | 6 | - | ||||||
| Security Deposit | 0 | 0 | 0 | 0 | ||||||
| Assets | 17 | 19 | 12 | 4 | ||||||
Liabilities Current | ||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 3 | 2 | 3 | 2 | ||||||
| Derivative Liabilities Current | 6 | 3 | 3 | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | ||||||
| Liabilities Current | 9 | 5 | 6 | 2 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | ||||||
| Long Term Debt Noncurrent | 6 | 6 | - | - | ||||||
| Contract With Customer Liability Noncurrent | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 16 | 13 | 7 | 4 | ||||||
Stockholders Equity | ||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 30 | 29 | 28 | 23 | ||||||
| Stockholders Equity Note Subscriptions Receivable | - | - | -1 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -29 | -23 | -22 | -23 | ||||||
| Stockholders Equity | 1 | 6 | 5 | 1 | ||||||
| Liabilities And Stockholders Equity | 17 | 19 | 12 | 4 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 30 | 30 | 29 | 28 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialTurn Therapeutics Inc. (TTRX) — SEC Financial Statements & Analysis
Turn Therapeutics Inc. (TTRX) is a pharmaceutical preparations company, incorporated in DE. Turn Therapeutics Inc. trades on Nasdaq as: TTRX. Turn Therapeutics Inc. (TTRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Turn Therapeutics Inc. carries a market cap of $217.45M, a P/E ratio of -21.71x, a P/B ratio of 316.58x, an enterprise value of $213.23M, and an EV/EBITDA multiple of -24.42x. On profitability, it posts a Return on Equity (ROE) of -1457.99% and a Return on Assets (ROA) of -59.05%. Per share, it reports EPS of $-0.34, diluted EPS of $-0.34, free cash flow per share of $-0.18, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 1.19x, a quick ratio of 1.17x, working capital of $1.66M, a debt-to-equity ratio of 23.69x, a debt ratio of 0.96, an interest coverage ratio of -36.18x, free cash flow of $-5.29M (TTM), and net debt of $-4.23M. Figures sourced from SEC EDGAR.
- Market Cap
- $217.45M
- P/E TTM
- -21.71x
- EPS TTM
- $-0.34
- P/B TTM
- 316.58x
- ROE TTM
- -1457.99%
- ROA TTM
- -59.05%
- Debt To Equity
- 23.69x
- Free Cash Flow TTM
- $-5.29M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Turn Therapeutics Inc. in?
Turn Therapeutics Inc. (TTRX) operates in the Pharmaceutical Preparations industry.
What exchange does TTRX trade on?
Turn Therapeutics Inc. (TTRX) trades on the Nasdaq.
Where is Turn Therapeutics Inc. incorporated?
Turn Therapeutics Inc. is incorporated in DE.
When was Turn Therapeutics Inc. (TTRX)'s most recent SEC filing?
Turn Therapeutics Inc. (TTRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is TTRX's market cap?
Turn Therapeutics Inc. (TTRX) has a market capitalization of $217.45M as of 2026-06-30.
What is TTRX's EPS (earnings per share)?
Turn Therapeutics Inc. (TTRX)'s trailing twelve month EPS is $-0.34 as of 2026-06-30.
What is TTRX's ROE (return on equity)?
Turn Therapeutics Inc. (TTRX)'s trailing twelve month Return on Equity (ROE) is -1457.99% as of 2026-06-30.
What is TTRX's ROA (return on assets)?
Turn Therapeutics Inc. (TTRX)'s trailing twelve month Return on Assets (ROA) is -59.05% as of 2026-06-30.
What is TTRX's EV/EBITDA?
Turn Therapeutics Inc. (TTRX)'s trailing twelve month EV/EBITDA is -24.42x as of 2026-06-30.